Cronos Group Inc. CRON

Healthcare SIC 2833 - Medicinal Chemicals & Botanical Products NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Medicinal and Botanical Manufacturing derived Nasdaq

Cronos is incorporated under the laws of the Province of British Columbia with principal executive offices located at 4491 Concession Rd 12, Stayner, Ontario L0M 1S0. The Company's telephone number is +1-416-504-0004, the website is https://thecronosgroup.com/ and the investor relations section of the website is https://ir.thecronosgroup.com/. All references to Cronos' website are inactive references, are for informational purposes only and are not intended to incorporate any information from or referenced on its website into this Annual Report.

Cronos common shares are currently listed on the Toronto Stock Exchange ("TSX") and on the NASDAQ Global Market ("Nasdaq") under the trading symbol "CRON."

Last close 3.35 2026-10-23
Market cap $1.23B 2026-06-30 share count
52-week range 2.28 - 3.61

Valuation FY2025 figures against the last close

P/S8.4x
P/E—
P/FCF8,283.1x
EV/EBITDA—
Dividend yield—
Diluted EPS-0.02

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • Canada
  • Israel
  • Other countries
Revenue by geography, 3 categories over 3 years. The same figures are in the table below. FY2025 Canada, FY2025: 90.3M (61.6%) 62% Canada Israel, FY2025: 41.8M (28.5%) 29% Israel Other countries, FY2025: 14.5M (9.9%) 10% FY2024 Canada, FY2024: 82.4M (70.1%) 70% Israel, FY2024: 28.4M (24.1%) 24% Other countries, FY2024: 6.8M (5.8%) 6% FY2023 Canada, FY2023: 64.7M (74.2%) 74% Israel, FY2023: 21.1M (24.2%) 24% Other countries, FY2023: 1.4M (1.6%)
Region FY2025FY2024FY2023
Canada $90.3M $82.4M $64.7M
Israel $41.8M $28.4M $21.1M
Other countries $14.5M $6.8M $1.4M

As the company reported it, from the “Segment Information - Schedule of Revenue from External Customers by Geographic Areas and Cash and Cash Equivalents and Short-term Investments (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $146.6M$117.6M$87.2M$86.7M$64.6M$46.7M$23.8M$12.1M$3.1M—
Gross profit $62.8M$25.2M$11.9M$15.4M-$17.6M-$25.8M-$17.6M$6.2M$1.6M—
R&D $4.4M$4.2M$5.8M$13.1M$21.8M$20.4M$12.2M$1.8M$0—
SG&A $42.0M$46.5M$49.5M$67.7M$90.9M$80.6M$81.5M$13.3M$4.9M—
Total operating expenses $80.2M$101.7M$96.7M$126.9M$274.4M$193.6M$135.7M$26.7M$7.7M—
Operating income -$17.4M-$76.5M-$84.8M-$111.4M-$292.0M-$219.4M-$153.3M-$20.4M-$6.1M—
Interest expense ———$13.0K$27.0K$186.0K$1.2M$139.0K$101.0K—
Pre-tax income -$17.1M$36.6M-$73.7M-$121.0M-$128.5M-$73.3M$1.17B-$20.9M-$2.3M—
Income tax $14.2M$3.4M$3.2M$34.2M$431.0K$1.3M$0$0$862.0K—
Net income -$2.9M$40.0M-$73.9M-$168.7M-$396.1M-$73.1M$1.17B-$21.6M-$1.5M—
EPS, basic -0.020.11-0.19-0.45-1.07-0.213.76-0.12-0.01—
EPS, diluted -0.020.11-0.19-0.45-1.07-0.213.33-0.12-0.01—
Shares, diluted (wtd. avg.) 383.5M385.6M381.0M377.0M370.4M351.6M342.8M172.3M176.8M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $791.8M$858.8M$669.3M$764.6M$887.0M$1.08B$1.20B$23.9M$7.3M$2.6M
Short-term investments $40.0M$0$192.2M$113.1M$117.7M$211.8M$306.3M$0——
Receivables $34.1M$15.5M$14.0M$23.1M$22.1M$8.9M$4.6M$3.1M——
Inventory $46.8M$33.1M$30.5M$37.6M$32.8M$44.0M$38.0M$7.4M——
Total current assets $944.1M$936.1M$933.3M$960.2M$1.08B$1.37B$1.57B$39.9M——
Property, plant and equipment $145.9M$133.2M$59.5M$60.6M$74.1M$187.6M$159.9M$125.9M——
Goodwill $66.5M$63.5M$1.1M$1.0M$1.1M$179.5M$214.5M$1.3M$1.4M—
Other intangibles $8.9M$11.3M$21.1M$26.7M$18.1M$69.7M$71.2M$8.2M——
Total assets $1.20B$1.17B$1.14B$1.21B$1.40B$1.93B$2.09B$183.5M——
Accounts payable $11.6M$17.0M$12.1M$11.2M$11.1M$19.3M$9.2M$1.2M——
Total current liabilities $48.2M$49.7M$41.4M$68.1M$54.4M$206.8M$332.9M$33.3M——
Total liabilities $54.2M$55.3M$44.1M$72.0M$63.5M$217.5M$341.4M$34.9M——
Retained earnings $447.8M$457.7M$416.7M$490.7M$659.4M$1.06B$1.14B-$27.9M——
Total equity $1.09B$1.06B$1.10B$1.14B$1.33B$1.71B$1.75B$148.5M$63.7M$22.3M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $25.9M$18.8M-$42.8M-$88.9M-$153.6M-$144.9M-$131.2M-$7.5M-$4.3M—
Depreciation and amortisation $14.2M$9.3M$8.1M$13.1M$15.4M$7.0M$4.3M$1.9M$768.0K—
Stock-based compensation $7.0M$8.7M$8.8M$15.1M$10.2M$15.4M$11.6M$8.2M$1.9M—
Capital expenditure $25.7M$12.4M$2.5M$3.5M$11.1M$31.4M$38.7M$88.3M$32.9M—
Investing cash flow -$76.6M$175.1M-$59.5M-$1.8M-$28.9M$20.1M-$603.3M-$93.9M-$29.9M—
Financing cash flow -$19.9M-$1.2M-$1.0M-$2.9M-$13.4M-$3.1M$1.86B$122.1M$39.1M—
Buybacks $9.7M$0$0———————

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001656472-26-000021.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -500M 0 500M 1B 1.5B Revenue, FY2017: 3.1M Gross profit, FY2017: 1.6M Net income, FY2017: -1.5M Revenue, FY2018: 12.1M Gross profit, FY2018: 6.2M Net income, FY2018: -21.6M Revenue, FY2019: 23.8M Gross profit, FY2019: -17.6M Net income, FY2019: 1.2B Revenue, FY2020: 46.7M Gross profit, FY2020: -25.8M Net income, FY2020: -73.1M Revenue, FY2021: 64.6M Gross profit, FY2021: -17.6M Net income, FY2021: -396.1M Revenue, FY2022: 86.7M Gross profit, FY2022: 15.4M Net income, FY2022: -168.7M Revenue, FY2023: 87.2M Gross profit, FY2023: 11.9M Net income, FY2023: -73.9M Revenue, FY2024: 117.6M Gross profit, FY2024: 25.2M Net income, FY2024: 40M Revenue, FY2025: 146.6M Gross profit, FY2025: 62.8M Net income, FY2025: -2.9M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $3.1M $12.1M $23.8M $46.7M $64.6M $86.7M $87.2M $117.6M $146.6M
Gross profit — $1.6M $6.2M -$17.6M -$25.8M -$17.6M $15.4M $11.9M $25.2M $62.8M
Net income — -$1.5M -$21.6M $1.17B -$73.1M -$396.1M -$168.7M -$73.9M $40.0M -$2.9M

Recent filings and events

  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Shareholder vote Item 5.07
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Results announced Item 2.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Material agreement signed Item 1.01
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2833

TickerCompanyMarket capP/ERevenue growth
DFTX Definium Therapeutics, Inc. $4.79B — —
TRLV Trulieve Cannabis Corp. $2.01B — -0.4%
TLRY Tilray Brands, Inc. $382.7M — 11.5%
CGC Canopy Growth Corp $285.9M — —
USNA USANA HEALTH SCIENCES INC $257.9M 24.1x 8.3%
NAGE Niagen Bioscience, Inc. $192.3M 12.2x 29.9%
FTLF FITLIFE BRANDS, INC. $78.4M 13.3x 26.4%
BTMD biote Corp. $30.6M 1.4x -2.5%